

REMARKS

Claims 1-44 were prosecuted in the parent case, application Serial No. 09/628,966, and thus have been canceled from this continuation application.

The parent application was allowed on March 5, 2003 and is issuing on July 22, 2003 as U. S. Patent No. 6,596,527. New claims 45 to 65 have been added. Support for the new claims may be found in the specification, claims and drawings as originally filed, for example, at pages 6-7, 31-32, 38-46; in examples 2 and 3 at pages 84-85; in example 6 at pages 87; in Table 5 at pages 87-88; in FIGS. 2, 3 and 7; and in the sequence listing. No new matter has been added.

Thus, the active claims in this case are claims 45 -65. The claims are attached hereto as "Appendix A" for the Examiner's convenience.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSH:245USC1.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3081
(512) 536-4598 (facsimile)

Date: July 22, 2003

APPENDIX A: CLEAN COPY OF THE PENDING CLAIMS

45. An isolated sentrin- specific protease (SENp) polypeptide comprising the amino acid sequence $\text{PIH}^{\text{L}}/\text{R XVHW}$ wherein X is a glycine, lysine or glutamic acid.
46. The isolated polypeptide of claim 45, comprising at least 25 contiguous amino acid residues of SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 10.
47. The isolated polypeptide of claim 45, comprising at least 50 contiguous amino acid residues of SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 10.
48. The isolated polypeptide of claim 45, comprising at least 100 contiguous amino acid residues of SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 10.
49. The isolated polypeptide of claim 45, comprising at least 150 contiguous amino acid residues of SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 10.
50. The isolated polypeptide of claim 45, comprising at least 200 contiguous amino acid residues of SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 10.
51. The isolated polypeptide of claim 48, further comprising amino acid residues 400 to 509 of SEQ ID NO: 8.
52. The isolated polypeptide of claim 48, further comprising amino acid residues 535 to 643 of SEQ ID NO: 2.
53. The isolated polypeptide of claim 48, further comprising amino acid residues 461 to 568 of SEQ ID NO: 10.
54. The isolated polypeptide of claim 45, comprising SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 10.
55. An isolated polypeptide comprising a sentrin-specific protease SENP1.
56. The isolated SENP1 polypeptide of claim 55, comprising at least 25 contiguous amino acids of SEQ ID NO: 2.

57. The isolated polypeptide of claim 55, comprising at least 50 contiguous amino acids of SEQ ID NO: 2.
58. The isolated polypeptide of claim 55, comprising at least 100 contiguous amino acids of SEQ ID NO: 2.
59. The isolated polypeptide of claim 55, comprising at least 150 contiguous amino acids of SEQ ID NO: 2.
60. The isolated polypeptide of claim 55, comprising at least 200 contiguous amino acids of SEQ ID NO: 2.
61. The isolated polypeptide of claim 58, comprising amino acid residues 535 to 643 of SENP1.
62. The isolated polypeptide of claim 58, comprising amino acid residues 527 to 643 of SENP1.
63. The isolated polypeptide of claim 55, wherein the SENP1 polypeptide comprises SEQ ID NO: 2.
64. A method of purifying a sentric-specific protease SENP1 polypeptide from a sample comprising collecting a sentric-specific protease polypeptide sample; incubating the sample with an antibody that specifically binds the SENP1 polypeptide; and obtaining the SENP1 polypeptide.
65. The method of claim 64, wherein the purified SENP1 polypeptide comprises the amino acid sequence of SEQ ID NO: 2.